Tolicizumab在类风湿性关节炎中的应用

Therapy of tolicizumab in rheumatoid arthritis

类风湿关节炎是以滑膜炎、慢性系统性炎症反应及自身抗体分泌为特点的自身免疫性疾病。已有研究结果表明,过量表达的IL-6在类风湿关节炎起病与进展过程中发挥着重要作用。Tolicizumab是第1个人源性的IL-6受体抗体,通过特异性识别结合IL-6受体而阻断IL-6生物学活性,发挥抑制类风湿关节炎炎症反应的作用。大量临床试验证据表明,tocilizumab不仅能明显缓解类风湿关节炎的临床症状,而且能防止关节继续遭受破坏。

Rheumatoid arthritis（RA） is characterized by persistent synovitis,systemic chronic inflammation,and autoantibodies secretion.Over-expression of IL-6 has been shown to play an important role in RA.As the first humanized anti-human IL-6 receptor antibody,tolicizumab can be one of the perfect antirheumatic drugs,which can block IL-6 biological actions by binding IL-6 receptor through specific recognition.A large number of clinical studies illustrate that tocilizumab not only shows effects on improving symptoms of RA but also on preventing joint destruction of RA.